tirzepatide dosage maintenance TrimRX maintenance dosing for tirzepatide Question

DPP-4 Introduccin A pesar de los avances teraputicos en el manejo de la Diabetes Mellitus (DM) en los ltimos aos, ms del 60% de los pacientes no alcanzan valores de HbA1C menores al 7%

This Phase 3 trial showed tirzepatide, a GIP/GLP-1 dual receptor agonist, met the primary objective of non-inferiority versus dulaglutide, a GLP-1 receptor agonist, with an 8% lower rate of major adverse cardiovascular events (MACE) that included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight

Blood tests assess whether those changes are healthy or indicate a need for a dose adjustment

Concurrently, the activation of GIP receptors enhances sugar metabolism, ensuring better insulin regulation